Seralutinib for Treatment of Group 1 PAH

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Emerging PH Therapeutics: The Promise of a New Future

Seralutinib for Treatment of Group 1 PAH

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    While there are now many effective drug treatments for PAH and PH, new molecular pathways of disease offer horizons for novel therapeutic developments that may, alone or in combination with existing, approved medications, alter the process of PH as a disease. This program examines some of the bright lights on the horizon of PH treatment and emerging drug delivery approaches to getting PH medications to their intended site of action. The emergence of these new agents could radically alter the way we think about combination therapy for PAH and other forms of PH.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including cardiologists, pulmonologists, echocardiographers, sonographers, nurse practitioners and other clinicians involved in the management of patients with pulmonary hypertension.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Discuss how ongoing phase 3 and 4 trial results within the PH community will impact care moving forward  
    • Understand the potential of utilizing novel molecular mechanisms of disease to affect the pathological progression of PH and the potential for treatment combinations to attack parallel disease pathways
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
    This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. 

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Richard Channick, MD, chair for this educational event, receives research funds from Altavant, Aerovate, Respira, and Merck; and receives consulting fees from Altavant, Aerovate, Respira, and Merck.

    Ioana Preston, MD, chair for this educational event, receives funds from Janssen, Merck and United Therapeutics; and receives consulting fees from Aerovate, Altavant, Gossamer, Liquidia, Janssen, Merck, Respira and United Therapeutics.

    Sudarshan Rajagopal, MD, PhD, chair for this educational event, receives research funds from Janssen, United Therapeutics and Altavant; receives royalties and is a patent holder for Polarean; receives consulting fees from Aerami, Altavant, GossamerBio, Insmed, Janssen, Liquidia, Polarean, United Therapeutics and Visterra; and has ownership interest in Apie Therapeutics. 

    Rajan Saggar, MD, chair for this educational event, receives consulting fees from Janssen, Aerovate, United Therapeutics, Third Pole and Aria.

    Oksana A. Shlobin, MD, chair for this educational event, receives consulting fees from UT, Janssen, Bayer, Altavant, Aerami, Aerovate and Merck. 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Dixon W. Wilde, PhD, FAHA, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Actelion Pharmaceuticals US, Division of Janssen Pharmaceuticals and United Therapeutics Corporation.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 6/28/2023 through  6/28/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    An example of different system requirements. In this cme experience we require you to have a brain. This requirement can be selected for several segments for example in Longitudinal study of the brain training series.

    Please feel free to add your own requirements (System Requirement objects) and select them in invidual or several segments. When you change any Segment Requirement object it will be updated in all segments that have this requirement selected.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule18 Jun 2024